Cargando…

Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006270/ https://www.ncbi.nlm.nih.gov/pubmed/35404433 http://dx.doi.org/10.1182/bloodadvances.2021006915

Ejemplares similares

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
por: Bergstrand, Martin, et al.
Publicado: (2021)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022)

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
por: de Oliveira Boechat, Tiago, et al.
Publicado: (2023)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020)

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
por: Djulbegovic, Mia, et al.
Publicado: (2022)

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers
por: Hrdinová, Johana, et al.
Publicado: (2021)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
por: Dierickx, Daan, et al.
Publicado: (2023)

Kahn JM, Brazauskas R, Tecca HR, et al. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020;4(9):2084-2094.
Publicado: (2022)

Olin RL, Fretham C, Pasquini MC, et al. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020;4(12):2810-2820.
Publicado: (2022)

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
Publicado: (2022)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
por: Cardesa‐Salzmann, Teresa Marta, et al.
Publicado: (2022)

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab
por: Mellaza, Chloé, et al.
Publicado: (2020)

Bornhauser B, Cario G, Rinaldi A, et al. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Adv. 2020;4(17):4052-4064.
Publicado: (2022)

Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018)

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
por: Scully, Marie, et al.
Publicado: (2022)

The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
por: Miyakawa, Yoshitaka, et al.
Publicado: (2022)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011)

Dengue and Thrombotic Thrombocytopenic Purpura
por: Wiwanitkit, Viroj
Publicado: (2017)

Vaccination and Thrombotic Thrombocytopenic Purpura
por: Yavaşoğlu, İrfan
Publicado: (2020)

Hereditary Thrombotic Thrombocytopenic Purpura
por: Nusrat, Sanober, et al.
Publicado: (2023)

Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials
por: Chen, Bin, et al.
Publicado: (2022)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
por: Syed, Umer, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k7nb0vi83fmtivakotu1dnnutk